
How reliably can we use existing routine and ad hoc MFS data sources to evaluate the quality of care for head and neck cancer patients?

M F Roche, J Ridha, S Edwards, G Price, K Lloyd, S Forsey

Cancer Registration		Hospital Episode Statistics (HES)	
Strengths	Weaknesses	Strengths	Weaknesses
High levels of case ascertainment	Little staging data	National coverage (England)	 Some issues with accuracy of diagnostic
•UK wide coverage	•Only (usually) records treatments within six	 Mandatory return from NHS hospitals- linked to 	coding
 Sole source of population based incidence and survival 	months of diagnosis	payments	 Problems with coding of very complex head
data	 Problems with coding of very complex 	•Covers all inpatient and day case hospital admissions	and neck surgery
•All head and neck sub sites covered	head and neck cancer surgery	 Covers all surgical procedures (diagnostic, 	No staging data
 Reliable information on tumour type and date of 	 Lack of clinical detail for radiotherapy 	therapeutic, palliative)	 No information on quality of life or patient
diagnosis	treatments	•Reliable source of information about health service	experience
 Reliable information on date and place of initial 	 Incomplete information on chemotherapy 	utilisation	 Outpatient HES has less complete and
therapeutic surgery	No information on recurrences	 Most complete source of information about ethnicity 	reliable clinical information
 Reliable information on date and place of radiotherapy 	•No information on quality of life or patient	•Co-morbidity index can be derived	
•Reliable information on date, place and cause of death	experience		
Some examples of analyses using cancer			An analysis of oursidal data from UES

come examples of analyses using cancer

registration data



by Oxford Cancer Intelligence Unit on behalf of Department of Health, Based rown Copyright 2009. All rights reserved. Department of Health 1000202

OBJECTIVES: To describe the strengths and weaknesses of the available national data sources covering the quality and outcome of head and neck cancer care. To show examples of analyses from the main national data sources including the National Head and Neck Cancer Audit (DAHNO), national cancer registration system and HES (Hospital Episode Statistics).


To show how more detailed radiotherapy and chemotherapy data collected within one cancer network can supplement the national sources.

METHODS: The completeness and quality of information in DAHNO, the national cancer registration system and HES will be compared and contrasted. Examples will be given of how the different data sources can be used to contribute to the understanding of variations in the quality and outcome of care for head and neck cancer patients. The added value of the data on radiotherapy and chemotherapy which has been collected in one Cancer Network will be reviewed.

RESULTS: The routine national data sources (cancer registration and HES) provide information about almost all patients with a diagnosis of head and neck cancer but are incomplete for some key data items (e.g. stage) and are not sufficiently accurate for others (e.g. complex surgery). The DAHNO audit on the other hand has less complete case ascertainment (although it is improving year on year) but has more information on stage and more accurate recording of complex surgery. None of the national sources currently has detailed information about radiotherapy and chemotherapy. **CONCLUSIONS:** The routine and ad hoc data sources available at national level have different strengths and weaknesses. By combining data from these sources, we get a more complete and accurate picture of care. The lack of detailed standardised information on radiotherapy and chemotherapy at national level will be addressed within the next few years.

An analysis of surgical data from HES

Major mouth and throat cancer surgery HRGs 2008/09 by acute trust




National Head and Neck Cancer Audit (DAHNO)


Radiotherapy and Chemotherapy


Strengths


 90% case ascertainment in most recent year Best source of staging information Surgical data coded by clinical teams

Quality indicators for DAHNO data









Weaknesses


 Completeness of key data items still varies by Trust and Network •Only covers some head and neck cancer subsites

 Limited information on radiotherapy and chemotherapy Incomplete information on co-morbidity and

performance status

 Incomplete information on care provided by dieticians, speech therapists, clinical nurse specialists

Incomplete information on status at follow up



An analysis of surgical data from DAHNO


Percentage receiving each category of surgical procedure (including surgery to neck, and flap repair)				
Oral cavity patients - surgery summery	Count	Percentage of 635 patients with surgical procedure recorded		
Floor of mouth excision	108	17.0		
- of these 108, the number having neck dissection	55	8.7		
Buccal mucosa excision	68	10.7		
-of these 68, the number having neck dissection	26	4.1		
Patients having tongue procedures	255	40.2		
- of these 255, the number having neck dissection	116	18.3		
patients having total glossectomy	9	1.4		
actionte herving portiel alege enterner.	400	00.5		

Radiotherapy

From 1 April 2009, all providers of radiotherapy to NHS patients are required to submit the Radiotherapy Data Set (RTDS), linked to the Out Patient Commissioning Dataset, for every fraction of radiotherapy delivered to their patients. This will enable progress against the National Radiotherapy Advisory Group guidelines to be assessed, as well as providing an insight into variations in radiotherapy treatment across England. Ultimately the data will be a new source for cancer registration and will be included in the national cancer data repository.

Some examples of analyses of radiotherapy and chemotherapy data for Thames Valley **Cancer Network**


icitabine+cisplatin, reo 010 cohort 3, taxol+carboplatin, ted6421cohortb & vincristine




Chemotherapy

NCIN have been working towards the delivery of an agreed chemotherapy dataset for England. The dataset needs to be approved by the Information Standards Board and, if approved, would become a mandatory return from April 2012. The aim is to capture the agreed dataset from eprescribing systems.

Trusts within Thames Valley Cancer Network have been collecting clinically relevant data on radiotherapy and chemotherapy treatments for more than a decade. The locally agreed datasets are very close to the newly mandated Radiotherapy Dataset and the proposed dataset for chemotherapy though less detailed. The types of analyses that can be undertaken include analyses of radiotherapy and chemotherapy regimes by cancer site, provider and PCT, showing variations between providers and temporal trends.





OCIU

Oxford Cancer Intelligence Unit

OCIU is delivered by **Solutions for Public Health** (SPH). © Copyright SPH, 2010

